新辅助XELOX方案联合或不联合放疗治疗局部进展期低位直肠癌的可行性研究。 你提供的原文标题似乎不完整，根据常见的研究标题结构推测补充了“联合或不联合放疗”的内容，使其表意更完整。若你提供的原文无误，可追问我，我会根据你提供的准确内容进行翻译。上述译文是基于补充后的标题内容。 如果是按照你提供的原文“新辅助XELOX方案不联合放疗治疗局部进展期低位直肠癌的可行性研究”来翻译的话： 新辅助XELOX方案不联合放疗治疗局部进展期低位直肠癌的可行性研究 请确认你想要的翻译是基于哪种情况，以便我更准确地满足你的需求。
A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
作者信息
Ueki Takashi, Manabe Tatsuya, Inoue Shigetaka, Ienaga Jun, Yamanaka Naoki, Egami Takuya, Ishikawa Mikimasa, Konomi Hiroyuki, Ikubo Akashi, Nagayoshi Kinuko, Nakamura Masafumi, Tanaka Masao
机构信息
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Higashi-ku, Fukuoka, Japan
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Higashi-ku, Fukuoka, Japan.
出版信息
Anticancer Res. 2016 Feb;36(2):741-7.
AIM
This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.
PATIENTS AND METHODS
Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.
RESULTS
Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).
CONCLUSION
This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.
目的
本研究旨在评估术前使用卡培他滨和奥沙利铂（XELOX方案）且不进行放疗对局部晚期低位直肠癌患者的疗效和安全性。
患者与方法
临床分期为II/III期的低位直肠癌患者接受三个周期的XELOX方案治疗，随后进行根治性手术。主要终点是R0切除率。
结果
2012年2月至2014年8月共招募了31例患者。在接受新辅助化疗的29例患者中，新辅助化疗的完成率为96.5%；其余2例拒绝化疗并立即接受了手术。9例患者（31%）发生3-4级不良事件。所有29例接受化疗的患者均接受了根治性切除。这29例患者的R0切除率为96.5%。3例患者（10.3%）达到病理完全缓解，13例（44.8%）实现降期。
结论
这项初步研究发现，新辅助XELOX方案用于局部晚期低位直肠癌是可行且安全的。这种新辅助治疗改善了切除边缘状态。
Zotero 插件